Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, with lead asset AKY-1189's Phase Ib data expected Q1 2027 as a binary catalyst. My conservative base case yields $12/share equity value, well below the ~$20 market price, implying patient expansion is already priced in.
Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b Part 1 data in Q1 2027 and AKY-2519 ASCO poster presentations and phase 1b initiation in mid-2026. The company's approach aims to expand the radiopharmaceutical market beyond PSMA and SSTR2, leveraging alpha-emitting actinium-225 for broader tumor targeting potential.
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
The accelerated deployment of 5G is enhancing the prospects of the Zacks Semiconductors - Radio Frequency industry players like RF Industries (RFIL) and Akoustis Technologies (AKTS) despite challenging macroeconomic conditions.
The accelerated deployment of 5G is enhancing the prospects of the Zacks Semiconductors - Radio Frequency industry players like RF Industries (RFIL) and Akoustis Technologies (AKTS) despite challenging macroeconomic conditions.
Steer clear of stocks to avoid in order to effectively protect your investment portfolio. Moreover, the essence of investing is identifying the next high-flying stock and knowing which stocks to avoid.
There's no denying that penny stocks with high potential carry incredibly big risks. At the same time, that's why they're so appealing.
Akoustis Technologies (NASDAQ: AKTS ) stock is rocketing higher on Wednesday alongside the rollout of design updates from the radio frequency ( RF ) filter manufacturing company. Akoustis Technologies notes that it has redesigned its XBAW manufacturing process.